Premium
Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
Author(s) -
Bhat Mamatha,
Watt Kymberly D.
Publication year - 2015
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12559
Subject(s) - medicine , everolimus , sirolimus , immunosuppression , malignancy , transplantation , organ transplantation , solid organ , cancer , cancer research , oncology , immunology
The mammalian target of rapamycin (m TOR ) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through m TOR inhibitor‐based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the m TOR pathway, as it pertains to chemoprevention, can support a clinical role for m TOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.